A recent paper demonstrated the ability of a selective HDAC6 inhibitor to improve AD phenotypes, including tau hyperphosphorylation and aggregation, learning and memory deficits, and to display neuroprotective effects [39]. This evidence concerns the gene HDAC6 and Alzheimer disease.